Centre for Advanced Medical Products

A national centre focusing on process development, manufacturing, logistics and system challenges of advanced therapy medicinal products (ATMP)

Duration: 2018-2023

Operated in collaboration with SWElife-ATMP, a strategic project within SWElife

Duration: 2017-2020



www.atmpsweden.se



SWElife

OV/

Advanced therapy medicinal products (ATMP)



Pharmaceuticals based on:

- Gene Therapy products
- Cell Therapy products
- Tissue Engineered products

Potential for highly effective treatments, and even cure of severe conditions

Predicted to transform healthcare and become major Life Science industry

Great challenges due to complexity and uniqueness:

manufacturing, logistics, regulatory aspects, health economy, implementation in healthcare for clinical adoption





Vision:

CAMP is an internationally leading centre in facilitating the implementation of ATMP.

Purpose:

To promote human health through breakthrough innovations in academia, healthcare and industry.




A strong public-private partnership to accelerate new breakthrough ATMP therapies to patients.

A national infrastructure and ecosystem to support commercialization.

Strong R&D&I activities in Sweden to attract global interest and investments.

Founding CAMP Partnership





Current partnership



Academy and HealthCare:


Umeå University (coordinator) Karolinska University Hospital/ **Region Stockholm Region Skåne** Akademiska Sjukhuset/ Region Uppsala län Region Örebro län **Region Östergötland Region Västerbotten** Västra Götalandsregionen Karolinska Institutet Kungliga Tekniska Högskolan Linköping University **RISE Research Institutes of Sweden** University of Gothenburg

Industry:

Acousort AB AstraZeneca AB **Bristol Myers Squibb** Cellink AB **Cellseed Sweden AB** Cobra Biopharma Matfors AB Cytiva (former GE Healthcare) Idogen AB **IsletOne** LIF – The Swedish Pharmaceutical Industry Association MAGic Bioprocessing AB Medicon Village AB NextCell Pharma AB

Noricon AB
Novartis Sweden AB
Pfizer Innovations AB
Takara Bio Europe AB
Tataa Biocenter AB
Verigraft AB
VivaBioCell S.p.A.
Xintela AB
Your Special Delivery Service AB

Organisation & governance




Research and development program



Work packages (WP1-3): Technologies and infrastructure to support and accelerate the translation of new treatments based on ATMPs to clinical phase

Cross cutting priorities (CCP1-2): System aspects, Swedish challenges and opportunities **(operated within SWElife-ATMP project)**

Currently ca 20 collaboration projects in progress



Benefits of being a CAMP partner



- Ease of access to the Swedish ATMP R&D, clinical and regulatory/legal communities
- Access to collaborative projects addressing
 - critical scientific and technological aspects of ATMP development.
 - system challenges, such as regulatory aspects and health economy.
- Facilitated access to process development and production infrastructures – pre-GMP and GMP.
- The possibility to contribute strategic development of the ATMP community in Sweden.
- New business-to-business opportunities
- Competence development of personnel

Director: Jukka Lausmaa jukka.lausmaa@ri.se Scientific director: Pontus Blomberg pontus.blomberg@sll.se Coordinator: Paul Kingham paul.kingham@umu.se Communicator: Heather Main <u>heather.main@sll.se</u>





